RA Capital Management

RA Capital Management

Invests in healthcare, life sciences.

Overview

RA Capital Management channels capital and expertise into healthcare, life sciences, and planetary health companies across growth stages. It funds ventures from private seed rounds to public follow-ons and uses evidence-based investing to guide decisions. Its TechAtlas research engine and Raven incubator provide internal data and a collaborative platform for entrepreneurs to develop and commercialize ideas. The firm aims to grow value for its portfolio and stakeholders by supporting companies that advance health outcomes, managing over $10 billion in assets.

About RA Capital Management

Simplify's Rating
Why RA Capital Management is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Financial Services

Healthcare

Company Size

N/A

Company Stage

N/A

Total Funding

$39.4B

Headquarters

Boston, Massachusetts

Founded

2001

Get referred to RA Capital Management

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 2026 brought a 23.8% Parabilis stake and board access through Jake Simson.
  • RA Capital launched a $120M Planetary Health Fund and Structured Capital in 2026.
  • Plantible's USDA-backed $35M raise and Inhibikase's $50M ATM show active deployment.

What critics are saying

  • Inhibikase's $50M financing depends on topline IMPROVE-PAH data and warrant exercise.
  • Equillium's $35M PIPE and Parabilis's IPO stake expose RA to clinical volatility.
  • If biotech valuations reset, RA's $14.4B AUM and concentrated holdings face immediate markdowns.

What makes RA Capital Management unique

  • RA Capital deployed $650M into private financings in 2025 across healthcare and planetary health.
  • It spans seed, crossover, IPO, public markets, and structured capital financing.
  • Peter Kolchinsky's team combines scientific diligence with hands-on board support at portfolio companies.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$39.4B

Above

Industry Average

Funded Over

0 Rounds

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Company News

Fierce Biotech
Aug 10th, 2026
Regeneron backs $75M series A for antibody discovery startup Infinimmune

Infinimmune has raised $75 million in a series A funding round led by Regeneron Ventures. The company develops antibody discovery technology. The startup plans to use the capital to advance its antibody discovery platform. Regeneron's venture arm headlined the investment round.

Green Queen Media
Aug 6th, 2026
USDA backs Plantible Foods' $35M raise to scale duckweed Rubisco protein capacity fivefold

Plantible Foods has raised $35 million in USDA-backed financing to expand production of its duckweed-derived Rubisco protein. The San Diego startup secured $25 million in debt from X-Caliber Rural Capital, a USDA-licensed lender, plus $10 million in equity from RA Capital and existing investors including Piva Capital. The funding will finance up to 50 new greenhouses at Plantible's 100-acre Texas facility, increasing capacity fivefold to over 100,000 tonnes annually. The company's Rubi Protein ingredient, which received FDA clearance six months ago, offers functional properties matching egg whites whilst delivering a 70% nutritional yield. Duckweed grows in two to three days with minimal water use and contains all nine essential amino acids. Plantible has raised $92 million to date.

Fierce Biotech
Aug 4th, 2026
Sanofi-backed Expedition raises $115M series B to advance COPD drug into phase 2

Expedition Therapeutics has closed an oversubscribed $115 million series B funding round to advance its lead DPP1 inhibitor into phase 2 trials for chronic obstructive pulmonary disease (COPD). The financing attracted a roster of prominent investors. The company is developing a DPP1 inhibitor, a drug class that targets a specific enzyme involved in inflammatory diseases. The series B proceeds will support clinical development of Expedition's lead candidate as it progresses through mid-stage trials. Expedition is backed by Sanofi, though the pharmaceutical giant's participation in this particular funding round was not specified in the available information.

StreetInsider
Jul 30th, 2026
DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq

Châtillon, France, July 30, 2026 DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Capital...

GlobeNewswire
Jul 29th, 2026
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS

Acquisition brings into Processa’s pipeline Vidya’s lead asset, VT-7208, a next-generation, CNS-penetrant, once-daily, oral potentially best-in-class...

Recently Posted Jobs

Sign up to get curated job recommendations

RA Capital Management is Hiring for 11 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →